Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

NICE overturns negative Glivec guidance

Recommends drug for reimbursement in GIST four years after rejection

- PMLiVE

Novartis brings creative malaria campaign to Pinterest

Invites users to create their own mosquito-killing story

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

Novartis partners with NHS on eye service

Launches community programme in Bristol

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

Novartis gets EU nod for rare disease drug Signifor

Long-acting formulation of drug approved for growth disorder acromegaly

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

- PMLiVE

EMA appoints Luc Vanheel as head of administration

He joins with immediate effect

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

- PMLiVE

EMA leaderless as tribunal forces Guido Rasi out

Court annuls appointment of executive director due to selection process concerns

EU flag

EU watchdog raps EMA for redacted AbbVie data

Issues over the redaction of clinical study reports

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links